Healthcare
Live Price
Offline$0.00001
+0.00% today
1Y Change
-90.00%
Window
Jun 23, 2025 → Jun 15, 2026
Coverage: 247 bars · Jun 23, 2025 → Jun 15, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
PharmaRoth Labs, Inc. (ROTH) is a Healthcare stock with listed on OTC. The stock last traded around $0.00 and down 90.0% across the available one-year price window (Jun 23, 2025 → Jun 15, 2026). Baseline metrics include revenue growth of -31.1%, EPS growth of +66.7%, a dividend yield of 0.0%. What stands out right now is revenue -31.1%, EPS +66.7%, free cash flow 0.0% with operating margin -50.4% and ROIC 29.6%. Valuation is more restrained than many high-expectation growth names at price/sales 0.2. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines ROTH price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
ROTH
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
ROTH Max Drawdown
-99.00%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for ROTH and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$153.9K
-70.9% YoY
FY Net Income
-$425.2K
-46.1% YoY
Free Cash Flow
-$121.7K
Revenue Growth
-31.1%
EPS Growth
+66.7%
Gross Margin
40.0%
Net Margin
-50.4%
Income statement
USD
| Metric | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|
| Revenue | 182K | 263K | 87K | 529K | 154K |
| Gross Profit | 73K | 108K | 27K | 316K | 34K |
| Operating Income | -92K | -233K | -370K | -293K | -427K |
| EBITDA | -92K | -233K | -370K | -292K | -425K |
| Net Income | -92K | -233K | -370K | -291K | -425K |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|
| Cash & Equivalents | 1K | 762 | 824 | 6K | 623 |
| Total Assets | 304K | 207K | 209K | 291K | 161K |
| Total Liabilities | 863K | 700K | 678K | 650K | 595K |
| Shareholder Equity | -549K | -483K | -459K | -358K | -431K |
| Total Debt | 250K | 250K | 0 | 0 | 0 |
| Net Debt | 249K | 249K | -824 | -6K | -623 |
Cash flow positioning
Latest Full Year
Operating Cash Flow
122K
+43.3% YoY
Capital Expenditures
0
-100.0% YoY
Free Cash Flow
122K
Key ratios
Gross Margin
40.0%
Operating Margin
-50.4%
Net Margin
-50.4%
ROE
17.7%
Debt / Equity
-0.45x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.